Colin Freund - Chief Executive Officer


Colin Freund has over 20 years’ experience in the pharmaceutical and biotechnology industries, with a primary focus in oncology. Prior to joining MODRA Pharmaceuticals, Colin was Chief Executive Officer, QUE Oncology, Inc., which focused on the development of novel therapies for vasomotor symptoms for patients with breast cancer, a non-opioidal therapy for chemo-induced neuropathy, and several early stage anti-cancer therapies. Prior to QUE, Colin had senior business and corporate development roles at Transgene SA, Agennix Inc., and GPC Biotech AG, all of which focused on developing novel oncology therapeutics. Prior to joining Double Twist, Mr. Freund was a project manager at the Boston Consulting Group, San Francisco, CA, and London, UK, where he managed assignments in the healthcare and high technology practice areas. 

Colin Freund received his M.A. in Economics and Management Studies from the University of Cambridge (U.K.), and his M.B.A. from Stanford University (U.S.).


Eric van der Putten - Director


Eric van der Putten is partner at Aglaia Biomedical Ventures, a venture capital firm with a 100% focus on oncology therapeutics and diagnostics.  

He has 30 years of clinical research experience and started his career in 1983 as Head Trial Department of the Comprehensive Cancer Center Amsterdam. Between 1990 and 2000, he held several positions at companies specialized in electronic data collection systems for clinical research, as well as market research for the pharmaceutical industry.

In 2000 Eric joined NDDO Oncology, a spin-off company of the EORTC, where he was COO and CEO. After the acquisition of NDDO Oncology by INC Research in 2005, he became Vice President Oncology for Europe. Eric is one of the co-founders of SMS-oncology, a specialized oncology CRO established in 2007.


Jan Schellens, MD, PhD - Chief Medical Officer


Jan Schellens is co-founder of Modra Pharmaceuticals and is responsible for medical and clinical management. He was a medical oncologist, clinical pharmacologist, and head of the Department of Clinical Pharmacology (GCP-licensed) of the NKI-AvL, and Professor of Clinical Pharmacology at Utrecht University in the Netherlands.

Jan Schellens has authored more than 750 scientific publications. He has more than 20 years of experience in clinical drug research and over 15 years of experience in drug regulation as member of the Dutch Medicines Evaluation Board (CBG-MEB). He was member of the Scientific Advisory Group Oncology to the European Medicines Agency for 12 years, and was Chair between 2006 - 2012. Jan is an advisor to many pharmaceutical companies including AstraZeneca, Astex, Merck, Pfizer, Roche, Eisai and Clovis Pharma.


Edwin De Wit, MD - Head of Oncology Development


Dr. Edwin De Wit joined Modra from Celsion Corp., where he was the Senior Vice President and Head of Medical for Europe since 2015. Dr. De Wit has over 20 years of experience in clinical operations and research in the pharma and biotech industry and has held leadership roles in oncology clinical development at Onyx Pharmaceuticals, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer. His specialties include the design and implementation of strategic clinical development and medical affairs plans of novel anti-cancer agents in various stages of development.



Marianne Keessen - Project Director


Marianne Keessen has a clinical background in oncology, mainly focused on early phase clinical trials. Prior to Modra, she worked for over 25 years at the Netherlands Cancer Institute - Antoni van Leeuwenhoek (NKI-AVL) as a nurse practioner and project manager, and was project manager for a nationwide study in biogenetic research in oncology at the Center Personalized Cancer Treatment (CPCT). Marianne holds a masters degree in nursing, and an M.B.A. from the Erasmus University in Rotterdam.



Modra Pharmaceuticals Announces First Patients Treated in Phase IIa Metastatic Breast Cancer Trial
Read more

Modra's Unique Approach

improving patient lives    
Learn more


Meet us at one of the following events:      
Read more